New Antibodies Turn 'Undruggable' KRAS Mutations into Visible Targets

New engineered antibodies can detect mutant-derived peptides that cancer cells naturally present on their surface, enabling immune targeting of mutations that lie inside the cell. Researchers applied this conce...



























